银华中证创新药产业ETF发起式联接A(012781)财务指标
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 本期已实现收益 |
-828,720.97 |
-2,384,067.93 |
-1,335,094.94 |
-173,767.43 |
| 本期利润 |
7,372,983.27 |
-4,602,136.79 |
-7,239,225.44 |
-2,131,057.64 |
| 加权平均基金份额本期利润 |
0.08 |
-0.10 |
-0.16 |
-0.09 |
| 本期加权平均净值利润率(%) |
12.63 |
-17.69 |
-28.46 |
-12.71 |
| 本期基金份额净值增长率(%) |
13.13 |
-14.13 |
-24.33 |
-11.59 |
| 期末可供分配利润 |
-32,848,114.86 |
-30,184,657.86 |
-20,836,821.11 |
-14,186,735.83 |
| 期末可供分配基金份额利润 |
-0.34 |
-0.42 |
-0.49 |
-0.32 |
| 期末基金资产净值 |
62,785,709.45 |
41,727,095.84 |
21,805,075.67 |
29,565,900.44 |
| 期末基金份额净值 |
0.66 |
0.58 |
0.51 |
0.68 |
| 基金份额累计净值增长率(%) |
-34.35 |
-41.97 |
-48.86 |
-32.42 |
微信公众号
证券之星APP
基本资料
